Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin HCL liposome
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Doxorubicin HCl liposome (brand name: Doxil) is a pegylated liposomal formulation of doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic. The active ingredient is encapsulated in microscopic phospholipid bilayer vesicles coated with methoxypolyethylene glycol (MPEG), known as STEALTH liposomes. This pegylation protects the drug from immune system detection and significantly extends its blood circulation time, allowing for preferential accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. Its mechanism of action involves intercalating into DNA and inhibiting topoisomerase II, which disrupts DNA replication and causes cell death. It is FDA-approved for the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma, and is investigated for other solid tumors including breast and endometrial cancers.
- Brand names
- DoxilCaelyxLipodox
- Other names
- doxorubicin HCL liposomepegylated liposomal doxorubicinPLDliposomal doxorubicin
02
Targets
Lipid bilayerTOP2B (DNA topoisomerase II beta)DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on doxorubicin HCL liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin HCL liposome.